BeautyHealth (NASDAQ:SKIN) exceeded revenue expectations in Q3 CY2025 with $70.7 million, down 10.3% YoY. Full-year revenue guidance is $296.5 million, surpassing analysts’ estimates by 0.8%. GAAP loss was $0.09 per share, in line with expectations. Adjusted EBITDA was $8.9 million, beating estimates by 12.6%. Operating margin improved to -8.8%.

The company’s CEO noted disciplined execution and foundation strengthening. BeautyHealth is known for its Hydrafacial product in the beauty health category. Sales performance is a key indicator of sustained growth. With $302 million in revenue last year, it faces challenges compared to larger competitors.

BeautyHealth’s revenue dropped 10.3% YoY but beat estimates by 2.6%. Analysts expect flat revenue in the next 12 months, below sector average. Despite some metrics exceeding expectations, the stock price rose by 16.7% post-reporting. Further analysis is needed to determine if it’s a good investment.

Read more at Yahoo Finance: BeautyHealth (NASDAQ:SKIN) Beats Q3 Sales Expectations, Stock Jumps 16.7%